Urologix, Inc. (ULGX) Stock Price & Analysis

Urologix, Inc. (ULGX) Healthcare & Pipeline Overview

Urologix, Inc. is a leader in developing minimally invasive medical devices for treating benign prostatic hyperplasia (BPH), leveraging innovative technologies like Cooled ThermoTherapy and Prostiva RF Therapy to enhance patient comfort and outcomes in urological care.

What Is the Investment Thesis for ULGX?

Urologix, Inc. presents a unique investment thesis centered on its specialized focus in the urology sector, particularly in treating benign prostatic hyperplasia (BPH). The company's innovative products, such as Cooled ThermoTherapy and Prostiva RF Therapy, leverage advanced technology to enhance treatment efficacy and patient comfort, providing a competitive edge in a growing market. The global market for BPH treatments is projected to expand significantly, driven by an aging population and increasing prevalence of urological disorders. Urologix's existing intellectual property and established market presence position it well to capitalize on this growth. However, potential investors should be aware of the company's financial challenges, including a negative profit margin of -53.4% and a minimal market capitalization of $2,182, indicating significant financial distress. Monitoring future financial filings and strategic initiatives will be crucial for assessing the company's recovery potential and long-term viability.

Based on FMP financials and quantitative analysis

ULGX Key Highlights

Market Cap: $0.00B indicating a distressed financial position.

• Profit Margin: -53.4%, reflecting ongoing financial challenges.
• Gross Margin: 42.8%, which is above the industry average, indicating potential for profitability if revenues increase.
• Beta: -80.29, suggesting low correlation with market movements, which may appeal to certain risk-averse investors.
• No dividend yield, reflecting the company's focus on reinvestment rather than returning cash to shareholders.

Who Are ULGX's Competitors?

ULGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ULGX's Key Strengths?

Innovative product offerings tailored for BPH treatment.

• Strong intellectual property portfolio.
• Established presence in the urology market.
• Commitment to improving patient comfort and outcomes.

What Are ULGX's Weaknesses?

Negative profit margin indicating financial distress.

• Limited market capitalization restricting growth potential.
• Dependence on a narrow product line focused on BPH.
• Challenges in scaling operations due to financial constraints.

What Are the Key Risks for ULGX?

Financial-distress signal — its Altman Z-Score of -34.44 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.

What Threats Does ULGX Face?

• Intense competition from established medical device companies.
• Regulatory hurdles impacting product development timelines.
• Market volatility affecting funding and investment opportunities.
• Economic downturns leading to reduced healthcare spending.

What Are ULGX's Competitive Advantages?

• Proprietary technologies that enhance treatment efficacy and patient comfort.
• Established brand recognition in the urology medical device market.
• Strong intellectual property portfolio protecting innovations.
• Focus on minimally invasive procedures, appealing to patients and providers.
• Commitment to research and development fostering continuous innovation.

What Does ULGX Do?

Established in 1991 and headquartered in Minneapolis, Minnesota, Urologix, Inc. specializes in the development, production, promotion, and distribution of minimally invasive medical devices across the United States. The company has carved a niche in the healthcare sector by focusing on innovative solutions that target the treatment of obstructions and related symptoms caused by benign prostatic hyperplasia (BPH). Urologix's flagship offerings include Cooled ThermoTherapy, which utilizes microwave energy combined with a cooling mechanism to protect healthy tissues while effectively targeting problematic areas. This approach not only enhances treatment efficacy but also significantly improves patient comfort during procedures. Additionally, the Prostiva RF Therapy System directs radio frequency energy into the prostate gland, effectively eliminating problematic prostatic tissue and alleviating urethral constriction associated with BPH. Urologix, Inc. serves a diverse clientele, including healthcare professionals and patients, positioning itself as a trusted provider in the urology space. Over the years, the company has focused on expanding its product portfolio and enhancing its technological capabilities, aiming to address the growing demand for effective and comfortable treatment options in urological care. Despite facing challenges in the competitive landscape, Urologix remains committed to innovation and improving patient outcomes, making it a noteworthy player in the medical device industry.

What Products and Services Does ULGX Offer?

• Develops minimally invasive medical devices for urological conditions.
• Specializes in treatments for benign prostatic hyperplasia (BPH).
• Offers Cooled ThermoTherapy and Prostiva RF Therapy systems.
• Focuses on improving patient comfort and treatment outcomes.
• Promotes products to healthcare professionals and patients.
• Engages in research and development to innovate in the urology space.

How Does ULGX Make Money?

• Generates revenue through the sale of medical devices and treatment systems.
• Focuses on direct sales to healthcare providers and institutions.
• Invests in research and development to enhance product offerings.
• Utilizes marketing strategies to promote awareness of its solutions.
• Engages in partnerships to expand distribution and market reach.

What Industry Does ULGX Operate In?

The medical device industry, particularly in the urology segment, is witnessing significant growth due to increasing awareness of urological disorders and advancements in minimally invasive technologies. The global market for BPH treatments is expected to grow substantially, driven by an aging population and rising healthcare expenditures. Urologix, Inc. is strategically positioned within this expanding market, focusing on innovative solutions that cater to the specific needs of patients suffering from BPH. The competitive landscape includes several players, but Urologix's proprietary technologies and focus on patient comfort set it apart from traditional treatment methods, enhancing its market positioning.

Who Are ULGX's Key Customers?

• Healthcare professionals specializing in urology.
• Hospitals and clinics providing urological care.
• Patients suffering from benign prostatic hyperplasia (BPH).
• Medical institutions seeking innovative treatment options.
• Distributors of medical devices in the healthcare sector.

Company Profile

Urologix, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Minneapolis, US. The company is led by CEO Bryon Merade. ULGX has traded publicly since 1996.

Urologix, Inc. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 5.7% below estimates on average.

Urologix, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -34.44 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Urologix, Inc. stands at 232.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.86 means current liabilities exceed short-term assets, a liquidity point worth watching.

12 transactions · 1 purchases, 2 sales, 9 other transactions · 7 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

ULGX Financials

ULGX Latest News

ULGX Analyst Consensus

ULGX MoonshotScore

Official Resources